Which has stronger earnings and valuation, MXCT or TASK?

TaskUs has higher revenue and earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than TaskUs, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MaxCyte $33.03M 3.81 -$44.63M -$0.37 N/A TaskUs $1.18B 0.36 $102.28M $1.14 4.11

Is MXCT or TASK more profitable?

TaskUs has a net margin of 8.70% compared to MaxCyte's net margin of -121.16%. TaskUs' return on equity of 24.93% beat MaxCyte's return on equity. Company Net Margins Return on Equity Return on Assets MaxCyte -121.16% -20.03% -17.14% TaskUs 8.70% 24.93% 12.12%

Which has stronger earnings and valuation, OOMA or MXCT?

Ooma has higher revenue and earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than Ooma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ooma $273.60M 1.81 $6.46M $0.32 56.38 MaxCyte $33.03M 3.81 -$44.63M -$0.37 N/A

Is OOMA or MXCT more profitable?

Ooma has a net margin of 3.17% compared to MaxCyte's net margin of -121.16%. Ooma's return on equity of 20.21% beat MaxCyte's return on equity. Company Net Margins Return on Equity Return on Assets Ooma 3.17% 20.21% 9.79% MaxCyte -121.16% -20.03% -17.14%

Which has stronger earnings and valuation, UXIN or MXCT?

Uxin has higher revenue and earnings than MaxCyte. Uxin is trading at a lower price-to-earnings ratio than MaxCyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Uxin $463.27M 0.76 -$39.69M -$0.21 N/A MaxCyte $33.03M 3.81 -$44.63M -$0.37 N/A

Is UXIN or MXCT more profitable?

Uxin has a net margin of -8.46% compared to MaxCyte's net margin of -121.16%. Uxin's return on equity of 0.00% beat MaxCyte's return on equity. Company Net Margins Return on Equity Return on Assets Uxin -8.46% N/A -11.67% MaxCyte -121.16% -20.03% -17.14%

Do analysts prefer IMXI or MXCT?

MaxCyte has a consensus price target of $5.50, suggesting a potential upside of 368.09%. Given MaxCyte's stronger consensus rating and higher possible upside, analysts clearly believe MaxCyte is more favorable than International Money Express. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score International Money Express 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 MaxCyte 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20

MaxCyte (MXCT) Competitors

$1.18 -0.01 (-0.42%)

Closing price 04:00 PM Eastern

Extended Trading

$1.18 +0.00 (+0.43%)

As of 07:47 PM Eastern

Compare

MXCT vs. TASK, NEXN, OOMA, UXIN, and IMXI

Should you buy MaxCyte stock or one of its competitors? MarketBeat compares MaxCyte with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MaxCyte include TaskUs (TASK), Nexxen International (NEXN), Ooma (OOMA), Uxin (UXIN), and International Money Express (IMXI). These companies are all part of the "business services" industry.

How does MaxCyte compare to TaskUs?

MaxCyte (NASDAQ:MXCT) and TaskUs (NASDAQ:TASK) are both small-cap business services companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, media sentiment, dividends, earnings and risk.

In the previous week, TaskUs had 4 more articles in the media than MaxCyte. MarketBeat recorded 4 mentions for TaskUs and 0 mentions for MaxCyte. MaxCyte's average media sentiment score of 0.00 equaled TaskUs'average media sentiment score.

Company	Overall Sentiment
MaxCyte	Neutral
TaskUs	Neutral

68.8% of MaxCyte shares are owned by institutional investors. Comparatively, 44.6% of TaskUs shares are owned by institutional investors. 4.1% of MaxCyte shares are owned by insiders. Comparatively, 31.9% of TaskUs shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

MaxCyte presently has a consensus price target of $5.50, suggesting a potential upside of 368.09%. TaskUs has a consensus price target of $11.20, suggesting a potential upside of 138.81%. Given MaxCyte's stronger consensus rating and higher possible upside, equities research analysts clearly believe MaxCyte is more favorable than TaskUs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MaxCyte	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
TaskUs	2 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.13

TaskUs has a net margin of 8.70% compared to MaxCyte's net margin of -121.16%. TaskUs' return on equity of 24.93% beat MaxCyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MaxCyte	-121.16%	-20.03%	-17.14%
TaskUs	8.70%	24.93%	12.12%

MaxCyte has a beta of 1.48, indicating that its share price is 48% more volatile than the broader market. Comparatively, TaskUs has a beta of 1.85, indicating that its share price is 85% more volatile than the broader market.

TaskUs has higher revenue and earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than TaskUs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MaxCyte	$33.03M	3.81	-$44.63M	-$0.37	N/A
TaskUs	$1.18B	0.36	$102.28M	$1.14	4.11

Summary

TaskUs beats MaxCyte on 11 of the 16 factors compared between the two stocks.

How does MaxCyte compare to Nexxen International?

MaxCyte (NASDAQ:MXCT) and Nexxen International (NASDAQ:NEXN) are both small-cap business services companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, media sentiment, dividends and profitability.

68.8% of MaxCyte shares are owned by institutional investors. Comparatively, 54.2% of Nexxen International shares are owned by institutional investors. 4.1% of MaxCyte shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

MaxCyte currently has a consensus target price of $5.50, suggesting a potential upside of 368.09%. Nexxen International has a consensus target price of $11.17, suggesting a potential upside of 29.24%. Given MaxCyte's higher probable upside, equities research analysts plainly believe MaxCyte is more favorable than Nexxen International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MaxCyte	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Nexxen International	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80

In the previous week, Nexxen International had 17 more articles in the media than MaxCyte. MarketBeat recorded 17 mentions for Nexxen International and 0 mentions for MaxCyte. Nexxen International's average media sentiment score of 0.38 beat MaxCyte's score of 0.00 indicating that Nexxen International is being referred to more favorably in the news media.

Company	Overall Sentiment
MaxCyte	Neutral
Nexxen International	Neutral

MaxCyte has a beta of 1.48, suggesting that its stock price is 48% more volatile than the broader market. Comparatively, Nexxen International has a beta of 1.64, suggesting that its stock price is 64% more volatile than the broader market.

Nexxen International has a net margin of 4.85% compared to MaxCyte's net margin of -121.16%. Nexxen International's return on equity of 7.78% beat MaxCyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MaxCyte	-121.16%	-20.03%	-17.14%
Nexxen International	4.85%	7.78%	4.94%

Nexxen International has higher revenue and earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than Nexxen International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MaxCyte	$33.03M	3.81	-$44.63M	-$0.37	N/A
Nexxen International	$364.78M	1.33	$25.04M	$0.30	28.80

Summary

Nexxen International beats MaxCyte on 12 of the 16 factors compared between the two stocks.

How does MaxCyte compare to Ooma?

Ooma (NYSE:OOMA) and MaxCyte (NASDAQ:MXCT) are both small-cap business services companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, media sentiment, analyst recommendations and risk.

Ooma has a net margin of 3.17% compared to MaxCyte's net margin of -121.16%. Ooma's return on equity of 20.21% beat MaxCyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ooma	3.17%	20.21%	9.79%
MaxCyte	-121.16%	-20.03%	-17.14%

Ooma has a beta of 1.22, indicating that its stock price is 22% more volatile than the broader market. Comparatively, MaxCyte has a beta of 1.48, indicating that its stock price is 48% more volatile than the broader market.

80.4% of Ooma shares are owned by institutional investors. Comparatively, 68.8% of MaxCyte shares are owned by institutional investors. 9.9% of Ooma shares are owned by company insiders. Comparatively, 4.1% of MaxCyte shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Ooma currently has a consensus price target of $22.33, suggesting a potential upside of 23.80%. MaxCyte has a consensus price target of $5.50, suggesting a potential upside of 368.09%. Given MaxCyte's higher probable upside, analysts clearly believe MaxCyte is more favorable than Ooma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ooma	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67
MaxCyte	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Ooma has higher revenue and earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than Ooma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ooma	$273.60M	1.81	$6.46M	$0.32	56.38
MaxCyte	$33.03M	3.81	-$44.63M	-$0.37	N/A

In the previous week, Ooma's average media sentiment score of 0.00 equaled MaxCyte'saverage media sentiment score.

Company	Overall Sentiment
Ooma	Neutral
MaxCyte	Neutral

Summary

Ooma beats MaxCyte on 11 of the 14 factors compared between the two stocks.

How does MaxCyte compare to Uxin?

Uxin (NASDAQ:UXIN) and MaxCyte (NASDAQ:MXCT) are both small-cap business services companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment and earnings.

In the previous week, Uxin had 5 more articles in the media than MaxCyte. MarketBeat recorded 5 mentions for Uxin and 0 mentions for MaxCyte. Uxin's average media sentiment score of 0.08 beat MaxCyte's score of 0.00 indicating that Uxin is being referred to more favorably in the media.

Company	Overall Sentiment
Uxin	Neutral
MaxCyte	Neutral

Uxin has higher revenue and earnings than MaxCyte. Uxin is trading at a lower price-to-earnings ratio than MaxCyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Uxin	$463.27M	0.76	-$39.69M	-$0.21	N/A
MaxCyte	$33.03M	3.81	-$44.63M	-$0.37	N/A

Uxin has a beta of 0.81, suggesting that its stock price is 19% less volatile than the broader market. Comparatively, MaxCyte has a beta of 1.48, suggesting that its stock price is 48% more volatile than the broader market.

22.4% of Uxin shares are held by institutional investors. Comparatively, 68.8% of MaxCyte shares are held by institutional investors. 62.9% of Uxin shares are held by insiders. Comparatively, 4.1% of MaxCyte shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Uxin presently has a consensus target price of $4.50, suggesting a potential upside of 177.78%. MaxCyte has a consensus target price of $5.50, suggesting a potential upside of 368.09%. Given MaxCyte's stronger consensus rating and higher possible upside, analysts plainly believe MaxCyte is more favorable than Uxin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Uxin	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
MaxCyte	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Uxin has a net margin of -8.46% compared to MaxCyte's net margin of -121.16%. Uxin's return on equity of 0.00% beat MaxCyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Uxin	-8.46%	N/A	-11.67%
MaxCyte	-121.16%	-20.03%	-17.14%

Summary

Uxin beats MaxCyte on 9 of the 16 factors compared between the two stocks.

How does MaxCyte compare to International Money Express?

International Money Express (NASDAQ:IMXI) and MaxCyte (NASDAQ:MXCT) are both small-cap business services companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, risk and analyst recommendations.

86.7% of International Money Express shares are held by institutional investors. Comparatively, 68.8% of MaxCyte shares are held by institutional investors. 5.1% of International Money Express shares are held by insiders. Comparatively, 4.1% of MaxCyte shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

International Money Express has a net margin of 4.34% compared to MaxCyte's net margin of -121.16%. International Money Express' return on equity of 23.26% beat MaxCyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
International Money Express	4.34%	23.26%	6.88%
MaxCyte	-121.16%	-20.03%	-17.14%

International Money Express has a beta of 0.75, indicating that its share price is 25% less volatile than the broader market. Comparatively, MaxCyte has a beta of 1.48, indicating that its share price is 48% more volatile than the broader market.

MaxCyte has a consensus price target of $5.50, suggesting a potential upside of 368.09%. Given MaxCyte's stronger consensus rating and higher possible upside, analysts clearly believe MaxCyte is more favorable than International Money Express.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
International Money Express	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
MaxCyte	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, International Money Express' average media sentiment score of 0.00 equaled MaxCyte'saverage media sentiment score.

Company	Overall Sentiment
International Money Express	Neutral
MaxCyte	Neutral

International Money Express has higher revenue and earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than International Money Express, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
International Money Express	$607.78M	0.68	$32.67M	$0.85	16.15
MaxCyte	$33.03M	3.81	-$44.63M	-$0.37	N/A

Summary

International Money Express beats MaxCyte on 9 of the 14 factors compared between the two stocks.

Get MaxCyte News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MXCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MXCT vs. The Competition

Export

Metric	MaxCyte	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$126.40M	$3.45B	$6.45B	$12.39B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	-3.18	19.75	24.92	23.97
Price / Sales	3.81	329.42	528.81	109.59
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	0.73	8.29	10.79	6.50
Net Income	-$44.63M	$23.85M	$3.56B	$336.88M
7 Day Performance	3.07%	5.21%	1.67%	-0.22%
1 Month Performance	12.98%	2.19%	0.43%	0.77%
1 Year Performance	-45.85%	60.99%	32.84%	31.57%

MaxCyte Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MXCT MaxCyte	3.6308 of 5 stars	$1.18 -0.4%	$5.50 +368.1%	-42.2%	$126.40M	$33.03M	N/A	80
TASK TaskUs	4.0088 of 5 stars	$5.36 -0.4%	$11.20 +109.0%	-70.1%	$492.69M	$1.18B	4.70	65,500	News Coverage
NEXN Nexxen International	4.5479 of 5 stars	$8.75 +0.7%	$10.69 +22.1%	-12.7%	$489.11M	$364.78M	14.25	895	High Trading Volume
OOMA Ooma	4.3077 of 5 stars	$17.34 +1.1%	$22.33 +28.8%	+41.3%	$471.62M	$273.60M	54.19	1,420
UXIN Uxin	3.5465 of 5 stars	$1.90 -10.4%	$4.50 +136.8%	-56.4%	$458.86M	$463.27M	N/A	2,437	Earnings Report Analyst Downgrade High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MXCT) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MaxCyte (MXCT) Competitors